Ceftazidime and the new SCE-2787 are parenteral cephalosporins with a broad antimicrobial spectrum. Pharmacokinetics, serum bactericidal activities, and side effects were investigated in a randomized crossover study. A total of 12 healthy volunteers received a 20-min infusion of 1.5 g of SCE-2787 or 2.0 g of ceftazidime. Serum and urine concentrations were determined by the bioassay method and by high-pressure liquid chromatography (HPLC) Infect. Dis. 136:196-204, 1977) against 40 clinically isolated strains. One hour after administration, we measured mean reciprocal bactericidal titers of SCE-2787 and ceftazidime, respectively, against Escherichia coli of 388 and 243, against KiebsieUla pneumoniae of 395 and 138, against Pseudomonas aeruginosa of 13.0 and 12.7, and against Staphylococcus aureus of 32.2 and 4.0. No severe side effects were observed in this single drug administration.
p-Lactam antibiotics are in wide use for treatment of various infectious diseases because of their potent antimicrobial activities as well as their favorable adverse effect profile (28, 39, 54) . A well-known parenteral broad-spectrum cephalosporin is ceftazidime, which is characterized by its broad antibacterial spectrum, including Pseudomonas aeruginosa (15, 17, 40, 49, 50, 52) . SCE-2787 is a new cephalosporin with a broader and better-balanced antimicrobial spectrum ranging widely from gram-positive to gramnegative bacteria, including Staphylococcus aureus and Pseudomonas aeruginosa (23) . The chemical structures of SCE-2787 and ceftazidime are shown in Fig. 1 . Both drugs are stable against various ,B-lactamases and have low affinities to these enzymes (5, 6, 41) . The present study with normal volunteers was performed to determine the basic pharmacokinetic data, the serum bactericidal activities, and the tolerance of SCE-2787 in comparison to ceftazidime in a single-dose administration design.
MATERIALS AND METHODS
Volunteers. A total of 12 healthy subjects (6 females and 6 males) participated in this study. They all were by ethnic * Corresponding author. origin Caucasians and had no known allergies to antimicrobial agents. Informed written consent was obtained from all volunteers. The study was approved by the local ethical committee according to German law. None of the females was pregnant (low human chorionic gonadotropin in urine), and none of the volunteers took any other antimicrobial agent or drug during 4 weeks preceding the study or during the study. Subjects had normal biochemical and hematological profiles, normal blood pressures, heart rates, and body temperatures, all of which were measured before the study, between days 1 and 2, and after the study. The volunteers fasted 12 h before drug administration (solid food as well as fluids), no tobacco products were allowed, and they avoided all alcoholic beverages the previous 24 h before antibiotic infusion. Mean age was 28 ± 50 to 300 mg/liter).
Recovery from serum was 96 to 103%, and that from urine was 99 to 104%. Specificity was confirmed by spectral analysis of the peak and complete enzymatic degradation with 1-lactamase type II from Bacillus subtilis. The extent of the degradation was 99% from serum and 95% from urine.
The ceftazidime concentrations were measured by HPLC on the basis of previously described methods (8, 25) . The analyte ceftazidime was separated by reversed-phase chromatography in a mobile phase which consisted of sodium acetate buffer plus acetonitrile. The A254 of the eluate was recorded. Sera were deproteinized by adding acetonitrile to the sample. Results were calculated with peak areas and external standardization. The detection limit was about 0.8 mg/liter. Linearity was given for concentrations of up to 250 mg/liter. The precision of the HPLC method was 4% at 117 mg/liter (coefficient of variation). The mean recovery was 91.4%. The identity of the peaks was confirmed by complete enzymatic degradation with 1-lactamase type II and by spectral analysis.
Bioassay. The bioassay method was based on an agar plate diffusion technique described by Reeves and Bywater (43) . Serum samples were assayed against standards prepared in activity-free pooled human serum. Phosphate buffer (pH 7.0) was used for the predilution of urine and urine standards. All samples and standards were tested in triplicate. SCE-2787 was detected in the concentration range from 180 to 0.6 mg/liter by using the test organism Escherichia coli NIHJ (IFO 14249) and Difco N agar (pH 7.4). The coefficient of variation was 2.65% at 5 mg/liter and 8% at 2.5 mg/liter. The detection limit was 0.45 mg/liter in serum and urine. The test organism Providencia rettgeri ATCC 9250 and MacConkey agar (pH 8.0) were used in the concentration range from 0.6 to 0.06 mg/liter. The coefficient of variation was 5.81% at 0.625 mg/liter, and the detection limit was 0.06 mg/liter in serum and 0.03 mg/liter in urine. Ceftazidime was evaluated in the concentration range from 0.9 to 0.3 mg/liter by using the test organism E. coli V 6311 and Difco N agar (pH 7.4). The coefficient of variation was 3.52% at 25 mg/liter and 2.99% at 6.25 mg/liter. The detection limit was 0.16 mg/liter in serum and urine. In the concentration range from 260 to 0.9 mg/liter, we used the test organism E. coli ATCC 25922 and Difco N agar (pH 7.4). The coefficient of variation was 2.75% at 6.25 mg/liter, and the detection limit was 0.6 mg/liter in serum and urine.
Protein binding. The protein binding of SCE-2787 was measured by micropartition system MPS-1 (Amicon GmbH, Witten, Germany) by using spiked samples containing 5 and 10 mg of SCE-2787 per liter. The concentration of the free fraction of SCE-2787 in the ultrafiltration partition was determined with the agar plate diffusion technique. The coefficient of variation was 5.8% at 5 mg/liter and 8.5% at 10 mg/liter. The centrifuge speed was 1,500 x g, the centrifuge time was 30 min, and the temperature was 25°C. The quantitative partitioning capability is reflected by retention of >99.9% of serum protein and <5% of L-thyroxine. The drug did not adsorb to the filter, and the ultrafiltration partition of SCE-2787 in buffer was 100%.
SBA. The serum bactericidal activity (SBA) was detected by using the microdilution method of Reller and Stratton (44) . All 3 5 a Nausea (n = 1) and watery stool (n = 6).
bVisual disturbance, increased sensitivity to light (n = 1); dizziness (n = 1); poor ability to concentrate (n = 4); and fatigue (n = 1). c Flush (n = 4) at the puncture site (n = 3), itching eyes (n = 1), and itching nose (n = 2). killed >99.6% of the initial inoculum was the SBA. In this study, the following freshly isolated pathogens were tested against sera from all volunteers 1 h after end of infusion (peak) and 8 h after end of infusion (trough): S. aureus (10 strains), E. coli (10 strains), Kiebsiella pneumoniae (10 strains), and P. aeruginosa (10 strains). All strains were freshly isolated from clinical materials by the Department of Microbiology (Klinikum Steglitz).
Pharmacokinetic analysis. Pharmacokinetic parameters were calculated both (i) with a noncompartmental analysis and (ii) on the basis of an open two-compartment model (16, 45) . (i) The area under the datum points (AUD) was calculated by the log trapezoidal rule, corrected for body weight and reference dose. (ii) We corrected the calculated pharmacokinetic constants for infusion time as described by Loo and Riegelmann by using the open two-compartment model: drugs were administered into and eliminated from a central compartment only. However, reversible drug distribution from the central space occurs simultaneously into one peripheral space (34) .
An iterative relative least-squares method was used to fit the constants to the experimental data of the serum concentration-time curve (29) (30) (31) . Serum drug concentrations were normalized for a body weight of 70 kg before determination of pharmacokinetic parameters. The area under the curve (AUC) was calculated by using the compartmental model (AUCO,) as the half-lives in distribution and elimination phases. The volume of distribution at steady state WSS3, in liters/70 kg = Vrs percentage of body weight) was detected by using the noncompartmental analysis. The alternative for biological half-lives, the mean residence time (MRT), was determined by using both pharmacokinetic models (10, 27) . The renal clearance (CLR) was total clearance x percent urine recovery/100. The total urine recovery is the result of the regression straight line, whose slope defines the data; they may be smaller than the urine recovery found by HPLC (e.g., see SCE-2787 [ Table 2] ).
Statistical analysis. Wilcoxon's test (signed-rank test for paired samples, two tailed) was used for statistical comparison. A probability (P) of <0.05 was considered significant.
RESULTS
Tolerance. No abnormal physical or laboratory findings were observed. All adverse effects were of a mild or moderate severity, were of short period, improved spontaneously, and recovered completely (Table 1) .
One volunteer developed a drug exanthema 2 and 9 days after infusion of ceftazidime and SCE-2787, respectively-a well-known intolerance effect of cephalosporins, which lasted for 2 days in this case.
Nonspecific circulatory disorders (chills, tachycardia, hypertension, nausea, dyspnea, cold perspiration, weak concentration, and dizziness) 6 h after receiving SCE-2787 led to discontinuation of blood sample collection from one volunteer; the relation to the study drug was unclear. The serum concentration data of SCE-2787 from 8 to 24 h and the serum bactericidal titer 8 h after end of infusion are representative of 11 volunteers only.
Single-dose kinetics. Drug concentrations and pharmacokinetic results in all tables are given on the basis of the HPLC. Comparison of the results obtained by bioassay and HPLC methods showed an excellent correlation for drug concentrations of SCE-2787 in serum (slope/intercept, 0.945/ -0.42; n = 170 [ Fig. 2] ) and urine (slope/intercept, 0.975/ +40; n = 48) (2). Predose samples of blood and urine showed no detectable activity. No metabolites of SCE-2787 or ceftazidime could be detected with the HPLC method. The control materials were blank serum and urine of the volunteers. The extent of degradation was 99% in serum and 95% in urine after enzymatic degredation with ,-lactamase from B. subtilis type II. of SCE-2787 was 118.4 ± 12.8 ml/min, and that of ceftazidime was 93.8 ± 11.5 ml/min. The CLR of SCE-2787 was 103.1 ± 12.3 ml/min, and that of ceftazidime was 80.6 ± 13.2 ml/min. The mean protein binding of SCE-2787 was 30.8% + 5.4%. Nearly two-thirds of the dose of both drugs was eliminated within 3 h (SCE-2787, 66.3% ± 5.4%; ceftazidime, 64.2% ± 6%). Twenty-four h after the end of infusion, the mean urine recovery of SCE-2787 was 87.8% ± 5.5% of the administered dose, and that of ceftazidime was 85.8% ± 6.3% (Fig. 4) .
The mean concentration at the end of the infusion showed a significant difference between 1.5 g of SCE-2787 and 2.0 g of ceftazidime (Table 2 ; Fig. 3 ) and also could be calculated significant differences of AUC, AUD, MRT, MRT*, V, Varea, CLrOT, and CLR (Table 2) . SCE-2787 and ceftazidime had similar initial and terminal half-life times, total urine recoveries, and nonrenal clearances ( Table 2) .
SBA. One hour after end of infusion, the serum concentrations of SCE-2787 and ceftazidime resulted in high mean reciprocal titers against E. coli and K pneumoniae. The mean reciprocal SBA titers of SCE-2787 and ceftazidime, respectively, were 388 and 243 against E. coli and 395 and 138 against K pneumoniae. Both antibiotics had a high mean peak titer of 13.0 (SCE-2787) and of 12.7 (ceftazidime) against P. aeruginosa. SCE-2787 showed an increased mean peak titer against S. aureus of 32.2, while ceftazidime showed a low titer of 4.0 (Fig. 5 and 6 ).
The mean minimal bactericidal concentration of SCE-2787 1 h after end of infusion was 0.12 mg/liter against E. coli, 0.11 mg/liter against K pneumoniae, 3.5 mg/liter against P. aeruginosa, and 1.4 mg/liter against S. aureus. The results of ceftazidime were 0.32 mg/liter against E. coli, 0.57 mg/liter against K pneumoniae, 6.19 mg/liter against P. aeruginosa, and 19.6 mg/liter against S. aureus. (Fig. 5 and 6 ).
All serum bactericidal titers were statistically significantly different between SCE-2787 and ceftazidime (P c 0.05), except for the results against P. aeruginosa (peak and trough level).
DISCUSSION
Tolerance. Both drugs were well tolerated, though nine volunteers who received 1.5 g of SCE-2787 and seven volunteers who received 2.0 g of ceftazidime complained of several minor adverse drug reactions. Most of the reported side effects showed no correlation with physical or laboratory findings or high concentrations of both drugs in urine or blood. The adverse effects referring to the central nervous system were atypical for this class of substances (13, 15, 37, 39) . Only local and peripheral reactions (flush at the puncture site and itching eyes and nose) were probably drug related, because they were recorded during or directly after the 20-min infusion, and they are well-known adverse effects of cephalosporins (1, 4, 14, 38) . Also, a well-known rare side effect of cephalosporins is the drug-induced exanthema that appeared 2 and 9 days, respectively, after infusion of ceftazidime and SCE-2787 in one subject (3, 22, 24, 36, 46) .
Seven volunteers who received 1.5 g of SCE-2787 and five volunteers who received 2.0 g of ceftazidime reported headaches. They may be enhanced or provoked by the long fasting state (about 15 h) or by the withdrawal of tobacco and caffeine-containing products from the subjects during the day of the study. These were also possible explanations for the nonspecific circulatory disorder in one volunteer, who didn't eat anything during the day of the study.
Four volunteers who received 1. (11, 20, 25, 51 Table 2) .
SBA. The SBA test has been used for many years to monitor antibiotic therapy, but there are many technical variables that influence the measurement of the SBA, and even in patients the drug levels fluctuate (42, 53) . However, a serum bactericidal titer of 21:8 is suggested to be associated with a significantly better therapeutic outcome in febrile cancer patients (26) , and in patients with granulocytopenia a titer of .1:16 seems to be necessary in gram-negative bacillary bacteremia (47) . In this study the SBA test took into account the ability of healthy volunteers to distribute, eliminate, and metabolize the antibiotic as well as to influence the bacterial growth by additional serum activity.
Though SCE-2787 and ceftazidime were eliminated quickly, they revealed high SBA titers against E. coli and K pneumoniae 8 h after end of infusion. Standiford et al. and other authors described comparable SBA results 1 and 6 h after infusion of ceftazidime (8, 12, 48) . These authors also described the same efficacy of ceftazidime against P. aeruginosa and S. aureus. The in vitro properties of ceftazidime against these four strains were first described by Wise et al. (52) . Our results were in the same range and were also reported by others (7, 18, 19, 21, 49) . SCE-2787 showed a minimal bactericidal concentration against P. aeruginosa after 440 min following the end of infusion, while ceftazidime showed it after 360 min. We observed an increased reciprocal titer of SCE-2787 of 32 against S. aureus 1 h after end of infusion compared with a low reciprocal titer of ceftazidime of 4 (8, 11, 48) . Iwahi et al.
reported comparable results of the in vitro and in vivo (in mice) activities of SCE-2787 against these four pathogens (23). SCE-2787 developed a minimal bactericidal concentration against S. aureus for a duration time longer than 600 min according to a twice-daily application, while ceftazidime
showed one for about 250 min. The serum bactericidal titers of SCE-2787 were generally better than those of ceftazidime against K pneumoniae, E. coli, and S. aureus and were equal against P. aeruginosa.
SCE-2787 and ceftazidime had similar pharmacokinetics with relative long elimination half-lives, were predominantly eliminated by the kidneys, and were well tolerated. Although SCE was administered in a lower dosage, both drugs offered VOL. 37, 1993 on August 26, 2017 by guest http://aac.asm.org/ Downloaded from approximately equal antibacterial efficacy against the tested gram-negative bacteria. The increased SBA titer of SCE-2787 against S. aureus demonstrated the broader antibacterial spectrum of this new cephalosporin, which could be of clinical importance in the treatment of serious nosocomial infections.
